<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283656</url>
  </required_header>
  <id_info>
    <org_study_id>15431</org_study_id>
    <nct_id>NCT04283656</nct_id>
  </id_info>
  <brief_title>Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women</brief_title>
  <official_title>A Prospective, Randomized, Three-period Crossover, Interaction Study to Evaluate the Pharmacokinetics of Doravirine and Tenofovir Disoproxil Fumarate Co-administered With Cross-sex Hormonal Therapy in Adult HIV-negative Transgender Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transgender women living with Human Immunodeficiency Virus (HIV) may prioritize&#xD;
      gender-affirming hormonal therapy over antiretroviral drug therapy. Hormonal therapy&#xD;
      typically consists of oral estradiol and spironolactone, which induce drug-metabolizing&#xD;
      enzymes after prolonged administration. This study evaluates the bi-directional potential&#xD;
      drug interaction between the antiretroviral drug, doravirine, when co-administered with&#xD;
      estradiol and spironolactone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2022</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Three period crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Doravirine area under the plasma concentration versus time curve from 0 hours to infinity (AUC0-∞)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 6, 12, 24, 48, 72, 96 hours post-dose for all participants</time_frame>
    <description>Doravirine AUC derived from plasma sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Doravirine maximum concentration (Cmax)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 6, 12, 24, 48, 72, 96 hours post-dose for all participants</time_frame>
    <description>Doravirine maximum observed concentration during the dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Doravirine trough concentration (C24)</measure>
    <time_frame>24 hours post-dose for all participants</time_frame>
    <description>Doravirine observed trough concentration during the dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tenofovir disoproxil fumarate area under the plasma concentration versus time curve from 0 hours to infinity (AUC0-∞)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 6, 12, 24, 48, 72, 96 hours post-dose for all participants</time_frame>
    <description>Tenofovir AUC derived from plasma sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tenofovir disoproxil fumarate maximum concentration (Cmax)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 6, 12, 24, 48, 72, 96 hours post-dose for all participants</time_frame>
    <description>Tenofovir maximum observed concentration during the dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tenofovir disoproxil fumarate trough concentration (C24)</measure>
    <time_frame>24 hours post-dose for all participants</time_frame>
    <description>Tenofovir observed trough concentration during the dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estradiol area under the plasma concentration versus time curve from 0 hours to infinity (AUC0-∞)</measure>
    <time_frame>Pre-dose, 0.5, 2, 6, 12, 24, 48, 72, 96 hours post-dose for all participants</time_frame>
    <description>Estradiol AUC derived from plasma sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estradiol maximum concentration (Cmax)</measure>
    <time_frame>Pre-dose, 0.5, 2, 6, 12, 24, 48, 72, 96 hours post-dose for all participants</time_frame>
    <description>Estradiol maximum observed concentration during the dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estradiol trough concentration (C12)</measure>
    <time_frame>12 hours post-dose for all participants</time_frame>
    <description>Estradiol observed trough concentration during the dosing interval</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Transgender Health</condition>
  <condition>Gender Dysphoria</condition>
  <condition>Transgender Women</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Period I</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence E, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone Sequence F, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period II</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence E and F, Treatment B: Single-dose estradiol and spironolactone co-administered with placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period III</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence E, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone Sequence F, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine/Lamivudine/Tenofovir</intervention_name>
    <description>100mg/300mg/300mg orally for one dose, daily</description>
    <arm_group_label>Period I</arm_group_label>
    <arm_group_label>Period III</arm_group_label>
    <other_name>Delstrigo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone 100mg</intervention_name>
    <description>200mg orally for two doses, twice-daily</description>
    <arm_group_label>Period I</arm_group_label>
    <arm_group_label>Period II</arm_group_label>
    <arm_group_label>Period III</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol 2mg</intervention_name>
    <description>4mg orally for two doses, twice-daily</description>
    <arm_group_label>Period I</arm_group_label>
    <arm_group_label>Period II</arm_group_label>
    <arm_group_label>Period III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for one dose, daily</description>
    <arm_group_label>Period II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy self-identified transgender women (male-to-female) between 18-45 years old at&#xD;
             the time of screening&#xD;
&#xD;
          -  Have not undergone an orchiectomy&#xD;
&#xD;
          -  Receiving oral estradiol and spironolactone for &gt;/= 3 months prior to study entry with&#xD;
             a self-reported adherence to prescribed doses of &gt;/= 90%&#xD;
&#xD;
          -  Agree to abstain from alcohol consumption throughout the duration of the study&#xD;
&#xD;
          -  Be willing to briefly interrupt hormonal therapy prior to and during the study&#xD;
&#xD;
          -  If on pre-exposure prophylaxis (PrEP) therapy containing tenofovir alafenamide or&#xD;
             tenofovir disoproxil fumarate, willing to discontinue PrEP at least 2 weeks before&#xD;
             study start and for the duration of the study&#xD;
&#xD;
          -  Agree to use condoms for all sexual activity prior to the start and throughout the&#xD;
             duration of the study&#xD;
&#xD;
          -  Evidence of a personal signed and dated informed consent document indicating that the&#xD;
             participant has been informed of all pertinent aspects of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of clinically significant acute or chronic disease, that in the&#xD;
             investigator's opinion, would compromise the participant's safety during the study&#xD;
&#xD;
          -  Use of injectable or transdermal estradiol&#xD;
&#xD;
          -  Use of any other hormonal replacement therapy, wit h the exception of oral estradiol&#xD;
             and spironolactone&#xD;
&#xD;
          -  Current use of any antiretroviral drug. This will not be exclusionary if participants&#xD;
             reported discontinuing within 30 days of screening&#xD;
&#xD;
          -  Creatinine clearance &lt;/= 60 mL/min, as estimated by the Cockcroft-Gault equation&#xD;
&#xD;
          -  Known anaphylactic or severe systemic reactions to any components of doravirine,&#xD;
             lamivudine, or tenofovir disoproxil fumarate&#xD;
&#xD;
          -  Positive HIV, hepatitis B or Hepatitis C virus at screening. Evidence of prior&#xD;
             hepatitis B infection and immunity is not exclusionary. Positive hepatitis C antibody&#xD;
             with negative viral load or documented antiviral hepatitis C treatment with one post&#xD;
             treatment non-detectable hepatitis C viral load is not exclusionary&#xD;
&#xD;
          -  Recent significant blood or plasma donation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Transgender Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter K Kraft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edwin Lam, PharmD</last_name>
    <phone>(215) 955-9076</phone>
    <email>edwin.lam@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Unit at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Angela C Pallotto, RN, BSN</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 22, 2020</study_first_submitted>
  <study_first_submitted_qc>February 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thomas Jefferson University</investigator_affiliation>
    <investigator_full_name>Walter K. Kraft</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Gender Dysphoria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pharmacokinetic data will be updated in study outcome and results.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

